This article is more than 5 years old. Information may no longer be current.
Vorinostat plus standard immunoprophylaxis reduced GVHD after allogeneic HSCT
Click Here to Manage Email Alerts
The addition of vorinostat to standard immunoprophylaxis reduced the incidence of graft-versus-host disease in patients with hematologic malignancies who underwent related-donor, reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation, according to results of a single-arm, phase 1/2 trial.
Fifty patients (median age, 59 years) with an 8/8 or 7/8 HLA-matched related donor were assessable for response and toxic effects. An additional eight patients were included in the toxic effects analysis.
All patients received a conditioning regimen that consisted of 40 mg/m2 daily fludarabine for 4 days, as well as 3.2 mg/kg daily busulfan for 2 days.
Researchers also administered standard immunoprophylaxis of 1 g mycophenolate mofetil three times a day on days 0 through 28, and 0.03 mg/kg daily tacrolimus — titrated to a goal level of 8 to 12 ng/mL — on days –3 to 180.
Treatment with vorinostat (Zolinza, Merck) commenced 10 days before HSCT and continued until day 100. Patients received twice-daily 100 mg or 200 mg doses.
Incidence of grade 2 through grade 4 acute GVHD by day 100 served as the primary endpoint.
All patients engrafted neutrophils and platelets after HSCT.
Researchers calculated a 22% cumulative incidence (95% CI, 13%-36%) of grade 2 to grade 4 acute GVHD.
Electrolyte disturbance (n=15), hyperglycemia (n=11), infections (n=6), mucositis (n=4) and increased activity of liver enzymes (n=3) were the most common non-hematologic adverse events.
Non-symptomatic thrombocytopenia after engraftment (n=9) was the most common hematologic grade 3 to grade 4 adverse event. All of these incidences were transient and resolved quickly, researchers wrote.
“Vorinostat combined with standard GVHD prophylaxis for patients undergoing related-donor reduced-intensity conditional HSCT is safe and feasible,” the researchers concluded. “This regimen, consistent with experimental observations, seems to result in a low cumulative incidence of clinically significant GVHD, without major adverse events. Further randomized trials are warranted to confirm these findings in this patient population and in broader HSCT settings.”
Disclosure: The researchers report no relevant financial disclosures.
Click Here to Manage Email Alerts